ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty

Arcturus Therapeutics (ARCT) and partner CSL Seqirus, a renowned vaccine company, together reported encouraging results from a 12-month follow-up analysis of a late-stage study evaluating a booster dose of their self-amplifying (sa-mRNA) COVID-19 vaccine, ARCT-154. Following the news, the stock gained 5.4% on Monday and continued to gain another 2.5% in the after-market hours.Superior Efficacy Observed With ARCT’s Novel COVID-19 JabPer the data readout, treatment with ARCT-154 showed a stronger and longer-l ...